New cancer drug targets notorious KRAS mutation in first human trial
NCT ID NCT07455617
Summary
This is an early-stage study to test the safety and initial effects of a new drug called ABO2102 in adults with advanced solid tumors that have a specific genetic change called a KRAS mutation. The main goals are to find a safe dose and see how the body handles the drug, while also checking for any early signs that it might help shrink tumors. This is the first time the drug is being given to people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED / METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.